Critical Comparison: SCYNEXIS (NASDAQ:SCYX) and Celgene (CELG)

SCYNEXIS (NASDAQ: SCYX) and Celgene (NASDAQ:CELG) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Insider & Institutional Ownership

30.9% of SCYNEXIS shares are owned by institutional investors. Comparatively, 79.9% of Celgene shares are owned by institutional investors. 4.0% of SCYNEXIS shares are owned by company insiders. Comparatively, 1.0% of Celgene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SCYNEXIS and Celgene’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SCYNEXIS $260,000.00 203.22 -$29.98 million N/A N/A
Celgene $11.23 billion 7.20 $2.00 billion $4.24 24.21

Celgene has higher revenue and earnings than SCYNEXIS.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for SCYNEXIS and Celgene, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SCYNEXIS 0 1 5 0 2.83
Celgene 1 12 17 0 2.53

SCYNEXIS presently has a consensus price target of $9.50, indicating a potential upside of 413.51%. Celgene has a consensus price target of $130.14, indicating a potential upside of 26.78%. Given SCYNEXIS’s stronger consensus rating and higher possible upside, analysts plainly believe SCYNEXIS is more favorable than Celgene.

Profitability

This table compares SCYNEXIS and Celgene’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SCYNEXIS -8,569.46% -64.12% -37.45%
Celgene 27.36% 63.80% 17.45%

Volatility & Risk

SCYNEXIS has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Celgene has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.

Summary

Celgene beats SCYNEXIS on 8 of the 12 factors compared between the two stocks.

SCYNEXIS Company Profile

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply